A pathologist, a radiologist and a hepatologist walked into a bar Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology Saint Louis

Noninvasive Techniques for the Evaluation and Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation and Professional

Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Harris R, Harman DJ, Card TR, Aithal GP, Guha

M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based

Alternatives to Liver Biopsy for Assessing Liver Disease a report by Thierry Poynard Professor of Medicine, University of Paris The consensus conference statements recommend liver biopsy in the management

NASH: WHAT YOU NEED TO KNOW MARCELO KUGELMAS, MD, FACP SOUTH DENVER GASTROENTEROLOGY CENTER FOR DISEASES OF THE LIVER AND PANCREAS, SWEDISH MEDICAL CENTER CLINICAL ASSOCIATE PROFESSOR OF MEDICINE, UNIVERSITY

Received: November 4, 2015 Accepted: November 4, 2015 Published online: April 8, 2016 2016 The Author(s) Published by S. Karger GmbH, Freiburg 1662 4033/16/0092 0065$39.50/0 This article is licensed under

NASH UPDATE ON DIAGNOSTICS AND THERAPY Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine Conflicts of interest Salaried employee: of VCU Member of Board: McGuire VA Research Institute,

CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver

Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled

WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? Helena Cortez-Pinto Laboratório de Nutrição, FML, Serviço de Gastrenterologia, Hospital St Maria, Lisboa, Portugal EASL Governing Board:

Break the Liver Biopsy Habit Dirk Elston MD Professor and Chairman Department of Dermatology and Dermatologic Surgery Medical University of South Carolina No conflict of interest Father of one of my nurses:

Disease Burden of Non Alcoholic Fatty Liver Disease (NAFLD) Dr. H. Razavi May 31, 2017 First European NASH NAFLD Summit Disclosure: This work with funded by a multi-sponsored research grant from Intercept,

New insights into fatty liver disease Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Prevalence of NASH Global prevalence of NAFLD is 25% with highest prevalence in the Middle

LOGIQ S8 XDclear 2.0 Liver Procedures See & quantify liver disease in a single exam Clinical Challenge Liver disease affects millions of people worldwide, and the number is growing. Clinicians need a cost-effective,

Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multi-center Nonalcoholic Steatohepatitis Clinical Trial Michael

Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE The effect of aerobic exercise on serum level of liver enzymes

Nonalcoholic Fatty Liver Disease (NAFLD) What is Nonalcoholic Fatty Liver Disease? It is normal for the liver to contain some fat. Sometimes, however, too much fat can build up in the liver. When fat makes

Epicardial adipose tissue in children is associated with an unfavorable cardiometabolic risk profile, but is not a stronger indicator than BMI Schusterova I., Joppova E., Stromplova D., Fatulova N., Tohatyova

GLUCAGON-LIKE PEPTIDE-1 IN NONALCOHOLIC STEATOHEPATITIS By Dr MATTHEW JAMES ARMSTRONG MBChB(Hons) BSc(Hons) MRCP A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY

The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Professor of Medicine University of Chicago Chicago, Illinois Overview Initial assessment of liver disease How do you diagnose cirrhosis?